Adjuvant treatment options for patients with advanced renal cell carcinoma (RCC) following surgery are continually evolving, and new treatment options for different stages of RCC are being approved. It can be challenging for clinicians to remain up-to-date on these updates.

The goal of this program is to improve the knowledge and competence of learners in the optimal management of patients with renal cell carcinoma (RCC).

Adjuvant treatment options for patients with advanced renal cell carcinoma (RCC) following surgery are continually evolving, and new treatment options for different stages of RCC are being approved. It can be challenging for clinicians to remain up-to-date on these updates.

The goal of this program is to improve the knowledge and competence of learners in the optimal management of patients with RCC.

Clinicians may find it difficult to determine which single- or multi-agent therapies are most effective for patients with different kidney cancer histologies and risk groups. The NCCN Categories of Preference and Categories of Evidence and Consensus help to stratify the most effective treatment regimens by histology and risk status.

The goal of this activity is to improve the knowledge, confidence, and performance of learners to integrate recent findings into the treatment of patients with RCC.

The goal of this activity is to improve the knowledge, confidence, and performance of learners to integrate recent findings into the treatment of patients with RCC.

Because of hereditary RCC’s rarity, there is an overall lack of recommendations for diagnosing and managing patients who are suspected or confirmed to have the disease. However, because some hereditary RCC syndromes may be aggressive, it is important to effectively diagnose and manage patients as early as possible to limit associated morbidity and mortality.